{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T02:20:19Z","timestamp":1792981219552,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.amepre.2023.01.037","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:58:48Z","timestamp":1678409928000},"page":"19-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Buprenorphine After Nonfatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-3705","authenticated-orcid":false,"given":"Hillary","family":"Samples","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3422-0012","authenticated-orcid":false,"given":"Molly A.","family":"Nowels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-6203","authenticated-orcid":false,"given":"Arthur R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Olfson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amepre.2023.01.037_bib0001","unstructured":"MR Spencer and AM Mini\u00f1o, Drug Overdose Deaths in the United States, 2001\u20132021. NCHS Data Brief, no 457, National Center for Health Statistics; Hyattsville, MD, 122556, https:\/\/doi.org\/10.15620\/cdc."},{"key":"10.1016\/j.amepre.2023.01.037_bib0002","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.amepre.2023.01.037_bib0003","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.amepre.2023.01.037_bib0004","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2018.06.004","article-title":"Risks of fatal opioid overdose during the first year following nonfatal overdose","volume":"190","author":"Olfson","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"10.1016\/j.amepre.2023.01.037_bib0005","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/jamapsychiatry.2018.1471","article-title":"Causes of death after nonfatal opioid overdose [published correction appears in JAMA Psychiatry. 2018;75(8):867]","volume":"75","author":"Olfson","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.amepre.2023.01.037_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108484","article-title":"Causes of death among U.S. Veterans with a prior nonfatal opioid overdose","volume":"219","author":"Warfield","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.amepre.2023.01.037_bib0007","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.amepre.2020.02.012","article-title":"Mortality following nonfatal opioid and sedative\/hypnotic drug overdose","volume":"59","author":"Goldman-Mellor","year":"2020","journal-title":"Am J Prev Med"},{"issue":"4","key":"10.1016\/j.amepre.2023.01.037_bib0008","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/jech-2019-212915","article-title":"Individual and county-level variation in outcomes following non-fatal opioid-involved overdose","volume":"74","author":"Lowder","year":"2020","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.amepre.2023.01.037_bib0009","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.drugalcdep.2016.02.024","article-title":"Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs","volume":"162","author":"Caudarella","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.amepre.2023.01.037_bib0010","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1080\/08897077.2016.1152342","article-title":"Emergency department presentation and mortality rate due to overdose: a retrospective cohort study on nonfatal overdoses","volume":"37","author":"Pavarin","year":"2016","journal-title":"Subst Abus"},{"issue":"5","key":"10.1016\/j.amepre.2023.01.037_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.5852","article-title":"Incidence of treatment for opioid use disorder following nonfatal overdose in commercially insured patients","volume":"3","author":"Kilaru","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.amepre.2023.01.037_bib0012","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s11606-020-05645-0","article-title":"Racial\/ethnic differences in the medical treatment of opioid use disorders within the VA Healthcare System following non-fatal opioid overdose","volume":"35","author":"Essien","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"8","key":"10.1016\/j.amepre.2023.01.037_bib0013","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2017.7818","article-title":"Medication-assisted treatment and opioid use before and after overdose in Pennsylvania Medicaid","volume":"318","author":"Frazier","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.amepre.2023.01.037_bib0014","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.annemergmed.2019.07.030","article-title":"Characteristics and receipt of medication treatment among young adults who experience a nonfatal opioid-related overdose","volume":"75","author":"Bagley","year":"2020","journal-title":"Ann Emerg Med"},{"issue":"6","key":"10.1016\/j.amepre.2023.01.037_bib0015","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s11606-018-4817-8","article-title":"Changes in outpatient services and medication use following a non-fatal opioid overdose in the West Virginia Medicaid program","volume":"34","author":"Koyawala","year":"2019","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.amepre.2023.01.037_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103176","article-title":"Engagement in drug treatment following nonfatal overdose among people who inject drugs in Appalachia","volume":"93","author":"Allen","year":"2021","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.amepre.2023.01.037_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107923","article-title":"The role of substance use disorders in experiencing a repeat opioid overdose, and substance use treatment patterns among patients with a non-fatal opioid overdose","volume":"209","author":"Karmali","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.amepre.2023.01.037_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108435","article-title":"Predictors of enrollment in opioid agonist therapy after opioid overdose or diagnosis with opioid use disorder: a cohort study","volume":"219","author":"Macmadu","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.amepre.2023.01.037_bib0019","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.annemergmed.2021.10.005","article-title":"Naloxone and buprenorphine prescribing following U.S. Emergency Department visits for suspected opioid overdose: August 2019 to April 2021","volume":"79","author":"Chua","year":"2022","journal-title":"Ann Emerg Med"},{"issue":"7","key":"10.1016\/j.amepre.2023.01.037_bib0020","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1080\/10826084.2021.1901933","article-title":"Buprenorphine Treatment Intake and Critical Encounters following a Nonfatal Opioid Overdose","volume":"56","author":"Victor","year":"2021","journal-title":"Subst Use Misuse"},{"issue":"3","key":"10.1016\/j.amepre.2023.01.037_bib0021","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.amepre.2023.01.037_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227966","article-title":"Socioeconomic risk factors for fatal opioid overdoses in the United States: findings from the Mortality Disparities in American Communities Study (MDAC)","volume":"15","author":"Altekruse","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.amepre.2023.01.037_bib0023","unstructured":"MACStats: Medicaid and CHIP Data Book. Medicaid and CHIP Payment and Access Commission (MACPAC). https:\/\/www.macpac.gov\/publication\/macstats-medicaid-and-chip-data-book-2\/. Accessed December 3, 2021."},{"key":"10.1016\/j.amepre.2023.01.037_bib0024","unstructured":"Centers for Medicare & Medicaid Services, Chronic pain in the Medicare population, Centers for Medicare & Medicaid Services; Baltimore, MD. https:\/\/www.cms.gov\/files\/document\/mcbs-2018-survey-file-chronic-pain-infographic.pdf. Published June 2020. Accessed December 2, 2021."},{"issue":"9","key":"10.1016\/j.amepre.2023.01.037_bib0025","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/MLR.0000000000000183","article-title":"Prescription opioid use among disabled Medicare beneficiaries: intensity, trends and regional variation","volume":"52","author":"Morden","year":"2014","journal-title":"Med Care"},{"key":"10.1016\/j.amepre.2023.01.037_bib0026","doi-asserted-by":"crossref","first-page":"k2833","DOI":"10.1136\/bmj.k2833","article-title":"Trends in opioid use in commercially insured and Medicare Advantage populations in 2007\u201316: retrospective cohort study [published correction appears in BMJ. 2018;363:k4825]","volume":"362","author":"Jeffery","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.amepre.2023.01.037_bib0027","unstructured":"Niles L, Blaz J, Ng J, et al. Medicare fee-for-service beneficiaries with opioid use disorder in 2018: disparities in prevalence by beneficiary characteristics. Centers for Medicare & Medicaid Services; Baltimore, MD. https:\/\/www.cms.gov\/files\/document\/oud-disparities-prevalence-2018-medicare-ffs-dh-002.pdf. Published December 2020. Accessed December 6, 2021."},{"key":"10.1016\/j.amepre.2023.01.037_bib0028","unstructured":"Tarazi W, Welch WP, Nguyen N, et al. Medicare beneficiary enrollment trends and demographic characteristics, Office of the Assistant Secretary for Planning and Evaluation, HHS; Washington, DC. https:\/\/aspe.hhs.gov\/reports\/medicare-enrollment. Published March 2, 2022. Accessed January 19, 2023."},{"issue":"6","key":"10.1016\/j.amepre.2023.01.037_bib0029","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3122\/jabfm.2018.06.180152","article-title":"Opioid overdose hospitalizations among Medicare-disability beneficiaries","volume":"31","author":"Peters","year":"2018","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.amepre.2023.01.037_bib0030","doi-asserted-by":"crossref","unstructured":"Song Z. Mortality quadrupled among opioid-driven hospitalizations, notably within lower-income and disabled white populations. Health Aff (Millwood). 2017;36(12):2054\u20132061. https:\/\/doi.org\/10.1377\/hlthaff.2017.0689.","DOI":"10.1377\/hlthaff.2017.0689"},{"issue":"11","key":"10.1016\/j.amepre.2023.01.037_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.15638","article-title":"Association of disability with mortality from opioid overdose among U.S. Medicare adults","volume":"2","author":"Kuo","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amepre.2023.01.037_bib0032","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/CLEP.S105613","article-title":"Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the U.S","volume":"9","author":"Mues","year":"2017","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.amepre.2023.01.037_bib0033","unstructured":"International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). National Center for Health Statistics, Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/nchs\/icd\/icd9cm.htm. Updated November 3, 2021. Accessed October 30, 2021."},{"key":"10.1016\/j.amepre.2023.01.037_bib0034","unstructured":"International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM). National Center for Health Statistics, Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/nchs\/icd\/icd-10-cm.htm. Updated October 17, 2022. Accessed October 30, 2022."},{"issue":"4","key":"10.1016\/j.amepre.2023.01.037_bib0035","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.mayocp.2013.12.008","article-title":"Epidemiology of emergency department visits for opioid overdose: a population-based study","volume":"89","author":"Hasegawa","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amepre.2023.01.037_bib0036","unstructured":"Alpha-Numeric HCPCS. Centers for Medicare & Medicaid Services. https:\/\/www.cms.gov\/Medicare\/Coding\/HCPCSReleaseCodeSets\/Alpha-Numeric-HCPCS. Updated May 9, 2022. Accessed October 30, 2022."},{"key":"10.1016\/j.amepre.2023.01.037_bib0037","series-title":"CPT Professional Edition: Current Procedural Terminology 2015","year":"2014"},{"key":"10.1016\/j.amepre.2023.01.037_bib0038","unstructured":"National Committee on Quality Assurance, 2020 quality rating system value set directory, National Committee on Quality Assurance; Washington, DC. https:\/\/store.ncqa.org\/2020-quality-rating-system-qrs-hedis-value-set-directory.html. Published 2019. Accessed October 10, 2021."},{"issue":"4","key":"10.1016\/j.amepre.2023.01.037_bib0039","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.amepre.2023.01.037_bib0040","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple cause of death, 1999-2020. http:\/\/wonder.cdc.gov\/mcd-icd10.html. Updated 2020. Accessed September 6, 2022."},{"key":"10.1016\/j.amepre.2023.01.037_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: a yearly assessment from 2010 to 2019","volume":"110","author":"Krawczyk","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"4","key":"10.1016\/j.amepre.2023.01.037_bib0042","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.amepre.2023.01.037_bib0043","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4996","article-title":"Overcoming barriers to prescribing buprenorphine in the emergency department","volume":"3","author":"Kim","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.amepre.2023.01.037_bib0044","first-page":"1784","article-title":"Barriers and facilitators for emergency department initiation of buprenorphine: a physician survey","volume":"37","author":"Lowenstein","year":"2019","journal-title":"Ann Emerg Med"},{"issue":"5","key":"10.1016\/j.amepre.2023.01.037_bib0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4561","article-title":"Barriers and facilitators to clinician readiness to provide emergency department\u2013initiated buprenorphine","volume":"3","author":"Hawk","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amepre.2023.01.037_bib0046","article-title":"User centered clinical decision support to implement initiation of buprenorphine for opioid use disorder in the emergency department: EMBED pragmatic cluster randomized controlled trial","volume":"377","author":"Melnick","year":"2022","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.amepre.2023.01.037_bib0047","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid","volume":"39","author":"Samples","year":"2020","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"10.1016\/j.amepre.2023.01.037_bib0048","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder","volume":"177","author":"Williams","year":"2020","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.amepre.2023.01.037_bib0049","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees","volume":"95","author":"Samples","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.amepre.2023.01.037_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108770","article-title":"Non-prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder","volume":"139","author":"Williams","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.amepre.2023.01.037_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108774","article-title":"Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: patterns, predictors, and association with buprenorphine treatment outcomes","volume":"139","author":"Samples","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"10","key":"10.1016\/j.amepre.2023.01.037_bib0052","article-title":"Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence","author":"Amato","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.amepre.2023.01.037_bib0053","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000193","article-title":"A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction","volume":"10","author":"Dugosh","year":"2016","journal-title":"J Addict Med"},{"key":"10.1016\/j.amepre.2023.01.037_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108923","article-title":"Adjunct interventions to standard medical management of buprenorphine in outpatient settings: a systematic review of the evidence","volume":"228","author":"Wyse","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.amepre.2023.01.037_bib0055","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/add.15233","article-title":"African Americans now outpace whites in opioid-involved overdose deaths: a comparison of temporal trends from 1999 to 2018","volume":"116","author":"Furr-Holden","year":"2021","journal-title":"Addiction"},{"issue":"15","key":"10.1016\/j.amepre.2023.01.037_bib0056","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMp2210121","article-title":"Transformingmanagement of opioid use disorder with universal treatment","volume":"387","author":"Gupta","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amepre.2023.01.037_bib0057","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amepre.2023.01.037_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102722","article-title":"Unintentional drug overdose: is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?","volume":"79","author":"Carlson","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"7","key":"10.1016\/j.amepre.2023.01.037_bib0059","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/add.14144","article-title":"Corrected U.S. opioid-involved drug poisoning deaths and mortality rates, 1999\u20132015","volume":"113","author":"Ruhm","year":"2018","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.amepre.2023.01.037_bib0060","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/ALN.0000000000000170","article-title":"Buprenorphine\u2013naloxone therapy in pain management","volume":"120","author":"Chen","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1016\/j.amepre.2023.01.037_bib0061","unstructured":"Disability and Health Data System (DHDS). Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Division of Human Development and Disability. https:\/\/dhds.cdc.gov. Updated May 19, 2022. Accessed September 29, 2021."}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379723000521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379723000521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:10:54Z","timestamp":1760083854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379723000521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0749379723000521"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2023.01.037","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine After Nonfatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2023.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}